Pharmaceuticals
EBR Systems Achieves First Enrollments in the WiSE-UP Study for Heart Failure Patients
The WiSE-UP post-approval study is gathering real-world evidence from commercially treated patients using the WiSE® left ventricular endocardial pacing (LVEP) system. Key Highlights: * The first two patients have now been enrolled in the WiSE-UP post-approval study by DrDevi Nair from St Bern...
2025-11-07 21:00
1599
Alebund Presents Phase 3 Trial Results of AP301 at the American Society of Nephrology (ASN) 2025 Congress
* Clinically and statistically significant superiority of AP301 maintenance dose versus ineffective low dose in reducing serum phosphate levels was established and AP301's efficacy is sustained throughout the 52 weeks of treatment. * The non-inferiority of AP301 to sevelamer carbonate in redu...
2025-11-07 20:00
2563
Harbour BioMed and Evinova China Announce Strategic AI Collaboration to Accelerate AI-Enabled Drug Development
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Nov. 7, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, andEvinova, a global ...
2025-11-07 14:00
2171
Fosun International Honored with Gold Award and Best Sustainability Team at The Asset Corporate Sustainability Leadership Awards 2025
HONG KONG, Nov. 7, 2025 /PRNewswire/ -- On the evening of 6 November 2025, The Asset, a renowned Asian financial magazine, hosted "The Asset Corporate Sustainability Leadership Awards 2025" ceremony inSingapore. Fosun International Limited ("Fosun International" or the "Company") (HKEX stock cod...
2025-11-07 09:00
4843
ACAAI 2025 | CS2015 (OX40L/TSLP Bispecific Antibody) Makes International Debut
SUZHOU, China, Nov. 6, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key disease areas, today announced that the Company will ...
2025-11-07 08:10
3493
Alphamab Oncology Showcases Cutting-edge Breakthroughs and Innovative Achievements at the 16th World ADC San Diego
SUZHOU, China, Nov. 6, 2025 /PRNewswire/ -- The 16th World ADC San Diego, held from November 3–6, 2025, brought together industry leaders inSan Diego, USA. Dr. Ting Xu, Founder, Chairman, and CEO of Alphamab Oncology, was invited to deliver a presentation titled "JSKN021: EGFR/HER3 Targeted Dual-...
2025-11-06 12:05
2230
The World's First Gene-Editing Therapy Targeting APOC3 for Hyperlipidemia
CorrectSequence Therapeutics' CS-121 Completed Dosing of First Chylomicronemia
Patient, Demonstrating Excellent Safety and Significant Efficacy
SHANGHAI, Nov. 6, 2025 /PRNewswire/ -- On November 6, 2025, Shanghai,
China, CorrectSequence Therapeutics Co., Ltd. (Correctseq
2025-11-06 08:00
2078
IDT Biologika Accelerates Global CDMO Expansion Manufacturing capabilities highlighted through consecutive participation in WVC, CPHI and BIO-Europe 2025
* Showcased end-to-end, customized manufacturing capabilities covering vaccines, gene and immune therapeutics * Strengthening global CDMO strategy through strategic synergy with SK bioscience * Sustainable growth expected, backed by European commercial manufacturing infrastructure and regul...
2025-11-05 21:00
3585
BioDlink Congratulates Lepu Biopharma on Securing Approval for the World's First Approved EGFR-Targeted ADC
* BioDlink helps Lepu Biopharma win China's marketing approval for EGFR-targeted ADC treating recurrent or metastatic nasopharyngeal carcinoma * This Becotatug Vedotin injection approval is BioDlink's first commercial ADC manufacturing initiative worldwide, validating its complex biologics co...
2025-11-05 21:00
3366
HanchorBio Presents Preclinical Data on HCB301 at SITC 2025
HCB301 is a first-in-class tri-specific immunotherapy targeting SIRPα-CD47, PD-1/PD-L1, and TGFβ; it shows potent macrophage activation, T-cell restoration, and tumor microenvironment remodeling in preclinical solid tumor models. TAIPEI, SHANGHAI, and SAN FRANCISCO, Nov. 5, 2025 /PRNewswire/ -- ...
2025-11-05 20:00
4255
XtalPi Subsidiary Ailux Announces Strategic Collaboration with Lilly to Advance Bispecific Antibody Development
SHANGHAI, Nov. 5, 2025 /PRNewswire/ -- Ailux, an innovator in AI-powered biologics and a wholly owned subsidiary of XtalPi (2228.HK), a global leader in AI drug discovery, today announced a strategic platform-based collaboration with Eli Lilly and Company ("Lilly") to accelerate the discovery and...
2025-11-05 18:00
3873
SingHealth Duke-NUS Launches Two New Global Health Centres to Advance Allied Health and Pharmacy Practices in Asia
* The Centre for Global Allied Health and Centre for Global Pharmacy will advance global health collaboration and capacity building, with a focus on strengthening allied health and pharmacy practices acrossAsia. * Both centres build on a legacy of more than 120 global health projects led by S...
2025-11-05 15:43
1655
KLN Appointed by Ego Pharmaceuticals as 4PL Partner in Hong Kong Strategic Collaboration to Deliver End-to-End Healthcare Supply Chain Solutions
HONG KONG, Nov. 5, 2025 /PRNewswire/ -- KLN Logistics Group Limited ('KLN'; Stock Code 0636.HK) is pleased to announce the appointment of its pharmaceutical arm, KLN Pharma (Hong Kong) Limited ('KLN Pharma'), as the fourth-party logistics (4PL) service provider for Australian skincare brand Ego ...
2025-11-05 13:42
1503
Ascletis Presents Full Analysis of Phase Ib Study of ASC30 Oral Tablet, Phase Ib Study of ASC30 Injection, and Preclinical Study of Combination of ASC31 and ASC47 at ObesityWeek® 2025
-Positive data from Phase Ib study of ASC30 oral tablet demonstrated up to 6.5% placebo-adjusted mean body weight reduction; safe and well tolerated with only mild-to-moderate gastrointestinal (GI) adverse events (AEs) across all multiple ascending dose (MAD) cohorts. -Phase Ib study data of ASC...
2025-11-05 08:10
2627
Grit Biotherapeutics Invited to Deliver Oral Presentation at ASH 2025 on Breakthrough In Vivo CAR-T Therapy GT801
BEIJING, Nov. 4, 2025 /PRNewswire/ -- Grit Biotherapeutics Co., Ltd. ("Grit Bio "), a leading clinical-stage biopharmaceutical company pioneering next-generation immunotherapies,today announced that its groundbreaking GT801 in vivo CAR-T program has been selected for an oral presentation at the u...
2025-11-04 21:15
2379
LakeShore Biopharma Enters into Definitive Agreement for Going-Private Transaction
BEIJING, Nov. 4, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd ("LakeShore Biopharma" or the "Company") (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics fo...
2025-11-04 20:04
4855
Hasten Sets a New Benchmark for Global Expansion by Building an End-to-End Asia-Pacific Healthcare Commercial Platform
SHANGHAI, Nov. 4, 2025 /PRNewswire/ -- Hasten Biopharmaceutical Co., Ltd. ("Hasten") announced that while completing 70 Marketing Authorization Transfers (MAT) for itsAsia-Pacific product portfolio, the company has established an end-to-end commercial network coveringSoutheast Asia, Australia, Ko...
2025-11-04 11:15
1637
Oral Presentation: Five Hematologic Malignancies Studies by Leads Biolabs to Be Featured at ASH 2025
NANJING, China, Nov. 4, 2025 /PRNewswire/ -- Leads Biolabs (Stock Code: 9887.HK) today announced that five research abstracts from its hematological oncology portfolio—including programs LBL–034 and LBL–076—have been accepted for presentation at the 67th Annual Meeting of the American Society of ...
2025-11-04 09:50
3706
CARsgen Announces Positive Clinical Data for Allogeneic CAR-T Products CT0596 and CT1190B
SHANGHAI, Nov. 3, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces clinical data for CT0596, an allogeneic BCMA-targeting CAR-T product candidate developed on its proprietary THANK-u Plus™ ...
2025-11-03 22:15
3493
EmeTerm Wristband Significantly Reduces Postoperative Nausea and Vomiting in Major Orthopedic Surgeries
VANCOUVER, BC, Nov. 3, 2025 /PRNewswire/ -- WAT Medical Enterprise Ltd. proudly announced the publication of a groundbreaking clinical trial inThe Journal of Bone & Joint Surgery (JBJS) which demonstrates the significant benefits of the EmeTerm wristband in reducing postoperative nausea and vomit...
2025-11-03 22:00
2858
Week's Top Stories
Most Reposted
NOVVA Group acquires 120 MWp Philippines solar project, anchoring its AI-era power platform in Southeast Asia
[Picked up by 302 media titles]
2026-06-19 11:12
Vietnam Explores Sustainable Aviation Fuel Development at International Conference in Hanoi
[Picked up by 301 media titles]
2026-06-25 14:33
Affinidi and CardInfoLink Put the Missing Trust Layer for AI Agents into Production
[Picked up by 301 media titles]
2026-06-19 09:00
IPD and ABB Help Power Sustainable Operations at New Sydney Fish Market
[Picked up by 298 media titles]
2026-06-22 17:40
SPHERE AX Partners with U.S. AI Semiconductor Company Blaize at the National Assembly
[Picked up by 293 media titles]
2026-06-24 18:00
Most Read
Resilience Actions, a Re Sustainability Initiative, Launches ECOHUB.IN to Power India's Climate and Circular Economy Innovation Ecosystem
2026-06-19 19:33
6243
LEIFRAS Co., Ltd. Reports Financial Results for the First Quarter of Fiscal Year 2026
2026-06-19 04:00
5769
